ZA200802495B - Alpa2C adrenoreceptor agonists - Google Patents
Alpa2C adrenoreceptor agonistsInfo
- Publication number
- ZA200802495B ZA200802495B ZA200802495A ZA200802495A ZA200802495B ZA 200802495 B ZA200802495 B ZA 200802495B ZA 200802495 A ZA200802495 A ZA 200802495A ZA 200802495 A ZA200802495 A ZA 200802495A ZA 200802495 B ZA200802495 B ZA 200802495B
- Authority
- ZA
- South Africa
- Prior art keywords
- alpa2c
- adrenoreceptor agonists
- adrenoreceptor
- agonists
- alpa2c adrenoreceptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71145305P | 2005-08-25 | 2005-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200802495B true ZA200802495B (en) | 2008-12-31 |
Family
ID=37668030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200802495A ZA200802495B (en) | 2005-08-25 | 2008-03-18 | Alpa2C adrenoreceptor agonists |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20070093477A1 (de) |
| EP (1) | EP1934203B1 (de) |
| JP (2) | JP2009506051A (de) |
| KR (1) | KR20080037070A (de) |
| CN (1) | CN101374830A (de) |
| AR (1) | AR057771A1 (de) |
| AT (1) | ATE478069T1 (de) |
| AU (1) | AU2006283109A1 (de) |
| BR (1) | BRPI0615021A2 (de) |
| CA (1) | CA2620173A1 (de) |
| DE (1) | DE602006016303D1 (de) |
| EC (1) | ECSP088221A (de) |
| ES (1) | ES2348997T3 (de) |
| IL (1) | IL189678A0 (de) |
| NO (1) | NO20081427L (de) |
| PE (1) | PE20070519A1 (de) |
| RU (1) | RU2008110902A (de) |
| SG (1) | SG165315A1 (de) |
| TW (1) | TWI329643B (de) |
| WO (1) | WO2007024949A2 (de) |
| ZA (1) | ZA200802495B (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
| ES2348997T3 (es) | 2005-08-25 | 2010-12-21 | Schering Corporation | Compuestos de 3,4-dihidro-2h-benzo[1,4]oxazina y 3,4-dihidro-2h-benzo[1,4]tiazina como agonistas del adrenorreceptor alfa2c. |
| JP5099814B2 (ja) * | 2006-02-02 | 2012-12-19 | 田辺三菱製薬株式会社 | 含窒素複素二環式化合物 |
| US7601716B2 (en) * | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| BRPI0718054A2 (pt) * | 2006-11-02 | 2013-11-05 | Hoffmann La Roche | 2-imidazóis substituídos como moduladores de receptores associados à traços de aminas |
| AU2007321376A1 (en) | 2006-11-16 | 2008-05-22 | F. Hoffmann-La Roche Ag | Substituted 4-imidazoles |
| BRPI0807961A2 (pt) * | 2007-02-13 | 2017-05-16 | Pharmacopeia Llc | agonista de alfa2c adrenorreceptor funcionalmente seletivos. |
| WO2008100459A1 (en) * | 2007-02-13 | 2008-08-21 | Schering Corporation | Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists |
| MX2009008776A (es) * | 2007-02-13 | 2009-08-25 | Schering Corp | Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos. |
| US7960376B2 (en) | 2007-09-14 | 2011-06-14 | Cara Therapeutics, Inc. | Benzo-fused heterocycles |
| UA105182C2 (ru) | 2008-07-03 | 2014-04-25 | Ньюрексон, Інк. | Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность |
| WO2010017120A1 (en) * | 2008-08-04 | 2010-02-11 | Schering Corporation | Cyclopropylchromene derivatives as modulators of the alpha-2c receptor |
| EP2341052A4 (de) * | 2008-09-05 | 2011-10-12 | Shionogi & Co | Ringkondensiertes morpholinderivat mit pi3k-hemmender wirkung |
| WO2010033495A2 (en) * | 2008-09-16 | 2010-03-25 | Schering Corporation | Functionally selective azanitrile alpha2c adrenoreceptor agonists |
| EP2356106A1 (de) | 2008-10-07 | 2011-08-17 | Schering Corporation | Biarylspiroaminooxazolinanaloga als modu modulatoren des alpha2c-adrenergen rezeptors |
| AR073629A1 (es) * | 2008-10-07 | 2010-11-17 | Schering Corp | Analogos de benzodioxano moduladores de receptores adrenergicos alfa 2c, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades respiratorias, alergicas, cardiacas, parkinson y/o alzheimer, entre otras |
| AU2010247412A1 (en) | 2009-05-15 | 2011-11-24 | Novartis Ag | 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 |
| MX2011012199A (es) * | 2009-05-15 | 2011-12-08 | Novartis Ag | Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona. |
| CN102471248B (zh) * | 2009-08-10 | 2015-01-07 | Bhi有限合伙公司 | 用于递送1,3-丙二磺酸的方法、化合物和组合物 |
| EP2646429B1 (de) * | 2010-12-01 | 2014-10-15 | Janssen Pharmaceutica NV | 4-substituierte cyclohexylamino-4-piperidinyl-acetamid-antagonisten von ccr2 |
| US20140315881A1 (en) * | 2011-07-29 | 2014-10-23 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| US9677892B2 (en) * | 2011-08-16 | 2017-06-13 | Walk Score Management LLC | System and method for assessing quality of transit networks at specified locations |
| WO2013076590A1 (en) * | 2011-11-23 | 2013-05-30 | Oxygen Healthcare Research Pvt. Ltd | Benzothiazine compounds as h3 receptor ligands |
| CN103588722A (zh) * | 2012-08-17 | 2014-02-19 | 苏州中科天马肽工程中心有限公司 | 6-硝基-2h-1,4-苯并恶嗪-3(4h)-酮的合成方法 |
| WO2019161224A1 (en) | 2018-02-15 | 2019-08-22 | GiraFpharma LLC | Heterocyclic compounds as kinase inhibitors |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| CA3150689A1 (en) * | 2019-08-14 | 2021-02-18 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| EP4103278A1 (de) * | 2020-02-12 | 2022-12-21 | Curadev Pharma Pvt. Ltd. | Niedermolekulare stachelantagonisten |
| PE20251235A1 (es) * | 2022-06-10 | 2025-04-29 | Sapiensbio Inc | Compuesto novedoso y composicion farmaceutica que comprende la misma como ingrediente activo |
| WO2024025896A2 (en) * | 2022-07-25 | 2024-02-01 | Evommune, Inc. | Protein kinase c (pkc) theta inhibitor compounds |
| WO2025099111A1 (en) | 2023-11-10 | 2025-05-15 | Wella Germany Gmbh | New telescoping syntheses of 6-hydroxy-benzomorpholine (3,4-dihydro-2h-1,4-benzoxazin-6-ol) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US5856106A (en) * | 1995-11-01 | 1999-01-05 | Biotransplant, Inc. | Determination of antibody production against administered therapeutic glycoproteins, especially monoclonal antibodies |
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| PT1036065E (pt) * | 1997-12-04 | 2004-09-30 | Allergan Inc | Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| US20030087962A1 (en) * | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
| TWI283669B (en) * | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| EP1365811A2 (de) * | 2000-07-14 | 2003-12-03 | Allergan, Inc. | Zusammensetzungen enthaltend alpha-2-adrenergische agonisten |
| US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| FI20022159A0 (fi) | 2002-12-05 | 2002-12-05 | Orion Corp | Uusia farmaseuttisia yhdisteitä |
| WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| WO2006036507A1 (en) * | 2004-09-24 | 2006-04-06 | Allergan, Inc. | 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
| ES2348997T3 (es) | 2005-08-25 | 2010-12-21 | Schering Corporation | Compuestos de 3,4-dihidro-2h-benzo[1,4]oxazina y 3,4-dihidro-2h-benzo[1,4]tiazina como agonistas del adrenorreceptor alfa2c. |
| US7700592B2 (en) * | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
-
2006
- 2006-08-23 ES ES06802156T patent/ES2348997T3/es not_active Expired - Lifetime
- 2006-08-23 AR ARP060103662A patent/AR057771A1/es not_active Application Discontinuation
- 2006-08-23 CA CA002620173A patent/CA2620173A1/en not_active Abandoned
- 2006-08-23 PE PE2006001024A patent/PE20070519A1/es not_active Application Discontinuation
- 2006-08-23 EP EP06802156A patent/EP1934203B1/de not_active Expired - Lifetime
- 2006-08-23 AT AT06802156T patent/ATE478069T1/de not_active IP Right Cessation
- 2006-08-23 WO PCT/US2006/032917 patent/WO2007024949A2/en not_active Ceased
- 2006-08-23 JP JP2008528110A patent/JP2009506051A/ja active Pending
- 2006-08-23 US US11/508,467 patent/US20070093477A1/en not_active Abandoned
- 2006-08-23 CN CNA2006800397664A patent/CN101374830A/zh active Pending
- 2006-08-23 BR BRPI0615021-7A patent/BRPI0615021A2/pt not_active IP Right Cessation
- 2006-08-23 RU RU2008110902/04A patent/RU2008110902A/ru not_active Application Discontinuation
- 2006-08-23 SG SG201006198-4A patent/SG165315A1/en unknown
- 2006-08-23 KR KR1020087005570A patent/KR20080037070A/ko not_active Withdrawn
- 2006-08-23 AU AU2006283109A patent/AU2006283109A1/en not_active Abandoned
- 2006-08-23 DE DE602006016303T patent/DE602006016303D1/de active Active
- 2006-08-24 TW TW095131073A patent/TWI329643B/zh active
-
2008
- 2008-02-21 IL IL189678A patent/IL189678A0/en unknown
- 2008-02-25 EC EC2008008221A patent/ECSP088221A/es unknown
- 2008-03-18 NO NO20081427A patent/NO20081427L/no not_active Application Discontinuation
- 2008-03-18 ZA ZA200802495A patent/ZA200802495B/xx unknown
- 2008-05-22 JP JP2008134858A patent/JP2009185016A/ja active Pending
-
2010
- 2010-03-12 US US12/722,879 patent/US7985748B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2620173A1 (en) | 2007-03-01 |
| WO2007024949A3 (en) | 2007-06-07 |
| KR20080037070A (ko) | 2008-04-29 |
| RU2008110902A (ru) | 2009-09-27 |
| AR057771A1 (es) | 2007-12-19 |
| DE602006016303D1 (de) | 2010-09-30 |
| US20070093477A1 (en) | 2007-04-26 |
| US7985748B2 (en) | 2011-07-26 |
| AU2006283109A1 (en) | 2007-03-01 |
| ES2348997T3 (es) | 2010-12-21 |
| EP1934203B1 (de) | 2010-08-18 |
| WO2007024949A2 (en) | 2007-03-01 |
| BRPI0615021A2 (pt) | 2011-04-26 |
| NO20081427L (no) | 2008-05-23 |
| ECSP088221A (es) | 2008-03-26 |
| HK1118812A1 (en) | 2009-02-20 |
| PE20070519A1 (es) | 2007-07-13 |
| EP1934203A2 (de) | 2008-06-25 |
| CN101374830A (zh) | 2009-02-25 |
| ATE478069T1 (de) | 2010-09-15 |
| TW200740799A (en) | 2007-11-01 |
| JP2009506051A (ja) | 2009-02-12 |
| TWI329643B (en) | 2010-09-01 |
| JP2009185016A (ja) | 2009-08-20 |
| IL189678A0 (en) | 2008-08-07 |
| US20100173823A1 (en) | 2010-07-08 |
| SG165315A1 (en) | 2010-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL189678A0 (en) | Alpha2c adrenoreceptor agonists | |
| TWI365078B (en) | Hemostat | |
| PL2175273T3 (pl) | Środek nadający kokumi | |
| IL184324A0 (en) | Pyy agonists and uses thereof | |
| SG126860A1 (en) | Surgical clip | |
| GB0522715D0 (en) | New use | |
| GB0521796D0 (en) | Gtgvr software application | |
| GB0505954D0 (en) | Novel use | |
| EP1889660A4 (de) | Ozonabbauendes mittel | |
| EP1927347A4 (de) | Mittel zur verringerung von bitterkeit | |
| GB0511190D0 (en) | Use | |
| GB0520176D0 (en) | Use | |
| GB0506001D0 (en) | Novel use | |
| GB0526031D0 (en) | Use | |
| GB0502250D0 (en) | Use | |
| GB0526552D0 (en) | New use | |
| GB0526032D0 (en) | Use | |
| EP1846443A4 (de) | Neuartige verwendung | |
| GB0508924D0 (en) | New use | |
| GB2422543B (en) | Louse-killing agents | |
| GB0503949D0 (en) | Use | |
| GB0507986D0 (en) | Use | |
| GB0503950D0 (en) | Use | |
| GB0507874D0 (en) | Use | |
| GB0500249D0 (en) | Poochy pad |